- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT03192072
A Rapid Test for Acute Respiratory Illness (Radical)
Evaluation of a Rapid Diagnostic Test for the Categorization of Acute Respiratory Illness
The primary purpose of this study is to support the development of a host response test for acute respiratory illness to identify bacterial, viral or NB/NV etiologies as compared to a clinical adjudication reference standard.
Secondary objectives include:
- Evaluate the effect of age on the performance of the HR-ARI test
- Evaluate the effect of race/ethnicity on the performance of the HR-ARI test
- Evaluate the effect of geography on the performance of the HR-ARI test
Studieöversikt
Status
Intervention / Behandling
Detaljerad beskrivning
The primary purpose of this study is to support the development of a host response test for acute respiratory illness to identify bacterial, viral or NB/NV etiologies as compared to a clinical adjudication reference standard.
Secondary objectives include:
- Evaluate the effect of age on the performance of the HR-ARI test
- Evaluate the effect of race/ethnicity on the performance of the HR-ARI test
- Evaluate the effect of geography on the performance of the HR-ARI test
Subjects will be identified in the Emergency Department of participating hospitals. Samples including nasopharyngeal swab, throat swab, blood, and urine will be obtained.
A case report form for each subject will be completed to include information regarding clinical characteristics, signs and symptoms of infection, presence of complications, and patient outcome. Baseline characteristics including preexisting conditions. Survival data will also be collected for each subject.
Samples collected will be used to characterize the patient's illness as either infectious or not, and if infectious, either bacterial or viral. Samples will also be used to measure changes in gene expression, referred to as the Host Response-Acute Respiratory Illness (HR-ARI) test.
The result of this test will be made in comparison to a retrospective review of the subject's clinical information. Results will not be used for any interventions and will not be released to subjects or their providers.
Because the study procedure includes only sample and data collection, the risks will be minimal and no different than encountered during routine clinical care.
The study was re-assessed in 2020 and applicable updates were made to the record.
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
California
-
Davis, California, Förenta staterna, 95616
- The University of California- Davis
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02115
- Brigham and Women's Hospital
-
Newton, Massachusetts, Förenta staterna, 02462
- Newton-Wellesley Hospital
-
-
Michigan
-
Detroit, Michigan, Förenta staterna, 48202
- Henry Ford Hospital
-
-
North Carolina
-
Chapel Hill, North Carolina, Förenta staterna, 27514
- The University of North Carolina at Chapel Hill
-
Durham, North Carolina, Förenta staterna, 27710
- Duke University Medical Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Förenta staterna, 15224
- Children's Hospital of Pittsburgh
-
-
Rhode Island
-
Providence, Rhode Island, Förenta staterna, 02903
- Rhode Island/Lifespan
-
-
Texas
-
Houston, Texas, Förenta staterna, 77030
- The University of Texas- Houston
-
-
Utah
-
Salt Lake City, Utah, Förenta staterna, 84132
- University of Utah Medical Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
A. Age 24 months or older
B. Acute respiratory illness of less than 28 days in duration.
C. Acute respiratory illness will be defined by at least two qualifying symptoms OR one qualifying symptom and at least 1 qualifying vital sign abnormality:
- Qualifying symptoms:Headache, rhinorrhea, nasal congestion, sneezing, sore throat, itchy or watery eyes, conjunctivitis, cough, shortness of breath, sputum production, chest pain, wheezing
- Qualifying Vital Signs: Age greater than or equal to 2 and less than 6:Tachycardia (HR greater than or equal to 110), Tachynpnea (RR greater than or equal to 20),Temperature greater than or equal to 38.5 degrees Celsius or less than or equal to 36 degrees Celsius. Age greater than or equal to 6: Tachycardia(HR greater than or equal to 90), Tachynpnea (RR greater than or equal to 20), Temperature greater than or equal to 38.5 degrees Celsius or less than or equal to 36 degrees Celsius.
D. Ability of the subject or legally authorized representative/parent to understand study procedures, and willing and able to comply with all required.
Exclusion Criteria:
A. Known or suspected infection at any other anatomic site requiring antibacterial therapy.
B. Any specific condition that in the judgment of the referring provider or the site investigator precludes participation because it could affect subject safety or ability of subject to participate in this trial.
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
---|---|
Subjects with Acute Respiratory Illness
Patients with acute respiratory illness identified in the Emergency Department
|
comparison to retrospective clinical adjudication
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Positive predictive value with reference standard (PPV)
Tidsram: Day 1
|
Number of assay positives that agree with the reference standard / [Number of assay positives that agree with the reference standard + Number of assay positives that disagree with the reference standard]
|
Day 1
|
Negative predictive value with the reference standard (NPV)
Tidsram: Day 1
|
Number of assay negatives that agree with the reference standard / [number of assay negatives that agree with the reference standard + number of assay negatives that disagree with the reference standard]
|
Day 1
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Overall agreement with the reference standard (OA)
Tidsram: Day 1
|
Number of samples that agree with the reference standard / all samples tested
|
Day 1
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- Pro00082317
- Pro00082322 (Annan identifierare: Duke UMC)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Bakteriella infektioner
-
Institut PasteurRekrytering
-
Duke UniversityAvslutadCentral Line-associated Bloodstream Infection (CLABSI)Förenta staterna
-
Catholic University of the Sacred HeartAvslutadCentral Line-associated Bloodstream Infection (CLABSI)
-
The University of Texas Health Science Center,...EurofinsAvslutadOdontogen Deep Space Neck InfectionFörenta staterna
-
Forest LaboratoriesIndragenCommunity-acquired Bacterial Pneumonia (CABP)
-
Princess Maxima Center for Pediatric OncologyUMC Utrecht; Dutch Cancer SocietyRekryteringCentral Line-associated Bloodstream Infection (CLABSI)Nederländerna
-
WockhardtACMAvslutadCommunity-acquired Bacterial Pneumonia (CABP)Förenta staterna
-
Furiex Pharmaceuticals, IncAvslutadCommunity-acquired Bacterial Pneumonia (CABP)Förenta staterna, Kanada, Colombia, Tyskland, Ungern, Polen
-
University of MalayaTeleflexRekryteringCLABSI - Central Line Associated Bloodstream InfectionMalaysia
-
Johns Hopkins UniversityAvslutadCLABSI - Central Line Associated Bloodstream InfectionFörenta staterna
Kliniska prövningar på Host Gene Expression
-
Pusan National University HospitalAvslutad
-
Clinica Universidad de Navarra, Universidad de...Centre de Recherche du Centre Hospitalier de l'Université de MontréalAvslutadCovid19 | HostaSpanien
-
Hyfe IncAktiv, inte rekryterande
-
Philips Consumer LifestyleAvslutad
-
Kessler FoundationHar inte rekryterat ännu
-
Candela CorporationRekryteringMeibomisk körteldysfunktion | Torra ögonsjukdomFörenta staterna, Argentina
-
Claret MedicalMeditrial Europe Ltd.Avslutad
-
Seno Medical Instruments Inc.UpphängdBröstcancerFörenta staterna
-
Kessler FoundationRekryteringAutismFörenta staterna
-
University of Massachusetts, WorcesterAvslutadBronkiektasisFörenta staterna